8-K
Dianthus Therapeutics, Inc. /DE/ (DNTH)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Act of 1934
Date of Report (Date of earliest event reported): October 1, 2020
MAGENTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38541 | 81-0724163 |
|---|---|---|
| (State or other jurisdiction of<br> <br>incorporation or organization) | (Commission<br> <br>File Number) | (I.R.S. Employer<br> <br>Identification Number) |
| 100 Technology Square<br> <br>Cambridge, Massachusetts | 02139 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (857) 242-0170
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br> <br>Symbol(s) | Name of each exchange<br> <br>on which registered |
|---|---|---|
| Common Stock, $0.001 Par Value | MGTA | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|---|
On October 1, 2020, as previously announced, Jason Ryan resigned as the Chief Operating and Financial Officer and Treasurer of Magenta Therapeutics, Inc. (the “Company”). Following Mr. Ryan’s resignation, Cindy Driscoll, the Company’s Vice President, Finance, has assumed the responsibilities of the principal financial officer and principal accounting officer of the Company on an interim basis.
Ms. Driscoll, 55, has served as the Company’s Vice President, Finance since June 2017. Prior to joining the Company, Ms. Driscoll worked at Tokai Pharmaceuticals, Inc. (“Tokai”), from June 2011 to June 2017, most recently as the vice president of finance from September 2014 to June 2017, where she oversaw all finance and administrative operations for the publicly-traded company, including supporting its 2014 initial public offering. Ms. Driscoll earned her undergraduate degree in economics from the State University of New York at Oswego and completed her Master of Business Administration at Suffolk University.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MAGENTA THERAPEUTICS, INC. | |
|---|---|
| Date: | October 2, 2020 |
| By: | /s/ Jason Gardner |
| Title: | President and Chief Executive Officer |
3